Simvastatin with immunotherapy for ARID1A-mutated stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the cholesterol drug simvastatin to standard immunotherapy and chemotherapy can help people with a specific type of gastroesophageal cancer (ARID1A mutated, HER2 negative). It is for patients who have not had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced or metastatic gastroesophageal cancer that is HER2 negative
- Your tumor has a specific gene change (ARID1A mutation) found at the time of your first diagnosis
- You have not had any prior chemotherapy, radiation, or surgery for this cancer (but surgery to remove the original tumor is allowed)
- You are able to take a combination of nivolumab (immunotherapy) and oxaliplatin-based chemotherapy, and your CPS score is 5 or higher
- You are not currently taking a statin or other cholesterol medication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a cholesterol-lowering statin drug (simvastatin or atorvastatin) to standard chemotherapy before surgery can improve survival in patients with advanced esophageal or gastric-junction cancer. Statins may help by reducing inflammation and improving how the body responds to cancer treatment.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
This trial tests a new approach where immune cells are injected directly into the tumor in people with a specific genetic change (ARID1a mutation) in their stomach or esophagus cancer. It aims to see if this treatment can help when used before any other cancer therapy.
Hear when a new Advanced or Metastatic Gastrooesophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.